SCORE2

There are 179 papers on SCORE2 in aging research: 5 trials and 141 observational studies in people, 28 reviews. The newest story, Nov 16, 2026: “Models estimate cardiovascular risk in Latin America and the Caribbean”.

Biomarker

179 papers study it54 more mention it57 findings

59 new papers in 30 daysSee all 233 papers on SCORE2

At a glance

SCORE2 predicts frailty, cardiovascular disease, and mortality in human cohorts and is linked with dementia. A screening-cohort preprint reports underprediction of absolute atherosclerotic cardiovascular risk; separate comparisons show that classification thresholds change how many people are labeled high risk.

57 findings in 37 papers from 2022 to 2026, 12 of them since August 2026

“Higher SCORE2 was associated with AT expression patterns involving immune responses, apoptosis, mTOR signaling, mitochondrial respiratory chain activity and glucose metabolism, including glycolysis, insulin signaling and pyruvate oxidation.”
Integrated adipose tissue transcriptomic and miRNA remodeling identifies molecular pathways associated with residual cardiovascular risk after weight lossCardiovascular diabetology2026doi:10.1186/s12933-026-03401-y
  • Human trial5
  • Humans141
  • In silico4

Interventions

8

Renal denervation

downin humans1

1 study
  1. Renal denervation decreases SCORE2 in humans (primary prevention subgroup with uncontrolled hypertension; compared with baseline) (Median estimated 10-year risk: 14.1% at baseline versus 11.3% at 6 months).

    “In the primary prevention subgroup, median 10-year SCORE2 risk decreased significantly from 14.1% at baseline to 11.3% at 6 months (p<0.001)”

    Human trialprimary prevention subgroup with uncontrolled hypertension; compared with baselineradiofrequency-, ultrasound-, or alcohol-based6 monthsn = 61

    Renal denervation improves metabolic parameters and reduces SCORE2-estimated cardiovascular risk in uncontrolled hypertension

    ESC Congress 2026 abstract

More on Renal denervation

Low-calorie diet

downin humans1

1 study
  1. Low-calorie diet decreases SCORE2 in humans (followed by 6-month dietary intervention).

    “Weight loss significantly improved body composition, insulin sensitivity, inflammation and SCORE2.”

    Human trialfollowed by 6-month dietary intervention8 weeks plus 6 monthsn = 66

    Integrated adipose tissue transcriptomic and miRNA remodeling identifies molecular pathways associated with residual cardiovascular risk after weight loss

    Cardiovascular diabetology

More on Low-calorie diet

Exercise

no changein humans1

1 study
  1. Exercise was not clearly linked with SCORE2 in individuals younger than 70 years (Harrell's C: 0.74 for all models).

    “Adding physical activity or diet or both to SCORE2 did not improve discrimination (Harrell's C: 0.74 for all models), calibration (slope: 1.06 for all), or reclassification”

    Humansin individuals younger than 70 years9.0 yearsn = 2,348

    Use of Mediterranean Diet Adherence and Physical Activity for Refining Cardiovascular Risk Prediction in the General Population - Insights from the CoLaus/PsyCoLaus Study

    European journal of preventive cardiology

More on Exercise

Dolutegravir + lamivudine

upin humans1

1 study
  1. Dolutegravir + lamivudine is linked with higher SCORE2 in humans (people with HIV) (+0.12).

    “increases of +0.12 in the DTG group ( P = 0.021)”

    Humanspeople with HIV48 weeks

    Changes in cardiovascular and metabolic risk scores after switching to DOR/3TC/TDF, DTG/3TC or BIC/FTC/TAF: results from a multicenter Italian cohort

    AIDS (London, England)

More on Dolutegravir + lamivudine

Bictegravir + emtricitabine + tenofovir alafenamide

upin humans1

1 study
  1. Bictegravir + emtricitabine + tenofovir alafenamide is linked with higher SCORE2 in humans (people with HIV) (+0.30).

    “there were increases of +0.12 in the DTG group ( P = 0.021) and +0.30 in the BIC group (<0.001)”

    Humanspeople with HIV48 weeks

    Changes in cardiovascular and metabolic risk scores after switching to DOR/3TC/TDF, DTG/3TC or BIC/FTC/TAF: results from a multicenter Italian cohort

    AIDS (London, England)

More on Bictegravir + emtricitabine + tenofovir alafenamide

Doravirine + lamivudine + tenofovir disoproxil fumarate

downin humans1

1 study
  1. Doravirine + lamivudine + tenofovir disoproxil fumarate is linked with lower SCORE2 in humans (people with HIV) (-0.35).

    “while we observed a decrease of -0.35 in the DOR group ( P < 0.001)”

    Humanspeople with HIV48 weeks

    Changes in cardiovascular and metabolic risk scores after switching to DOR/3TC/TDF, DTG/3TC or BIC/FTC/TAF: results from a multicenter Italian cohort

    AIDS (London, England)

More on Doravirine + lamivudine + tenofovir disoproxil fumarate

Planhasso

downin humans1

1 study
  1. Planhasso decreases SCORE2 in humans (overweight or obesity) (from 1.51% to 0.46%).

    “The cardiovascular risk estimated using SCORE2 decreased from 1.51% to 0.46% during follow-up.”

    Human trialoverweight or obesity12 months

    PlanHaSSO: Healthy Habits Plan against Overweight and Obesity. Research project for the development of a protocolized program for primary care

    Atencion primaria

More on Planhasso

Time since menopause

upin humans1

1 study
  1. Time since menopause is linked with better SCORE2 in humans (AUC 0.584 to 0.657).

    “Adding TSM or the metabolomic signature to SCORE2 improved 10‐year risk discrimination (area under the curve 0.584 to 0.657 and 0.660, respectively)”

    Humansfemalesn = 67,582

    Integrating menopause duration and plasma metabolomics enhances cardiovascular risk stratification in aging women

    npj aging

More on Time since menopause

Effects

3

High cardiovascular risk classification

downin humans1upin humans1

1 study
  1. SCORE2 is linked with lower high cardiovascular risk classification in humans (6.5% classified as high risk versus 58.8% with SCORE2 (2021); none classified as very high risk).

    “Application of the 2025 thresholds reversed this distribution: 93.5% were classified as low-moderate risk, 6.5% as high risk, and none as very high risk.”

    Humansprimary prevention; 2025 thresholds compared with SCORE2 (2021), using identical baseline datan = 413

    From SCORE-Belgium to SCORE2: impact of successive guideline updates on cardiovascular risk categorization

    Acta cardiologica

  2. SCORE2 is linked with higher high cardiovascular risk classification in humans (58.8% classified as high risk versus 11.6% with SCORE-Belgium).

    “With SCORE2 (2021), 58.8% were categorised as high risk and 7.3% as very high risk.”

    Humansprimary prevention; SCORE2 (2021) compared with SCORE-Belgium (2019), using identical baseline datan = 413

    From SCORE-Belgium to SCORE2: impact of successive guideline updates on cardiovascular risk categorization

    Acta cardiologica

Risk stratification

upin humans1

1 study
  1. SCORE2 improves risk stratification in humans (risk assessment in older individuals).

    “which enable improved stratification, particularly in older individuals”

    Reviewrisk assessment in older individuals

    ESC guidelines on dyslipidemia update 2025 : New recommendations for the practice

    Herz

Concordance index

no changein humans1

1 study
  1. SCORE2 was not clearly linked with concordance index in humans (East Asian population).

    “SCORE2/SCORE2-OP showed no improvement in Harrell's concordance index (C-index) compared with SCORE/SCORE-OP.”

    HumansEast Asian populationn = 324,384

    SCORE and SCORE2 in East Asian Population: A Performance Comparison

    JACC. Asia

Upstream

8

Vasomotor symptoms

no changein humans1

1 study
  1. Vasomotor symptoms were not clearly linked with SCORE2 in humans (multivariable linear regression) (beta 0.689, 95% CI −0.162 to 1.540).

    “vasomotor symptoms (beta 0.689, 95% CI −0.162 to 1.540) were not significantly associated with SCORE2 risk (%)”

    Humansmultivariable linear regressionfemalesn = 192

    Associations of Demographic and Menopause-Related Characteristics with SCORE2 Cardiovascular Risk Among Women Aged 45 to 55 Years: A Retrospective Analysis

    Cukurova Anestezi ve Cerrahi Bilimler Dergisi

Postmenopausal status

no changein humans1

1 study
  1. Postmenopausal status was not clearly linked with SCORE2 in humans (multivariable linear regression) (beta 0.542, 95% CI −0.633 to 1.717).

    “postmenopausal status (beta 0.542, 95% CI −0.633 to 1.717) and vasomotor symptoms (beta 0.689, 95% CI −0.162 to 1.540) were not significantly associated with SCORE2 risk (%)”

    Humansmultivariable linear regressionfemalesn = 192

    Associations of Demographic and Menopause-Related Characteristics with SCORE2 Cardiovascular Risk Among Women Aged 45 to 55 Years: A Retrospective Analysis

    Cukurova Anestezi ve Cerrahi Bilimler Dergisi

Epicardial adipose tissue volume normalized to total heart volume

upin humans1

1 study
  1. Epicardial adipose tissue volume normalized to total heart volume is linked with higher SCORE2 in population cohort.

    “High-risk by SCORE2 and the prevalence of obstructive CAD increased over quartiles of EATVh in the population cohort”

    Humansin population cohort

    Reference values for epicardial adipose tissue: data from 27,500 CT scans in the general population and symptomatic patients

    European journal of radiology

More on Epicardial adipose tissue volume normalized to total heart volume

Diastolic blood pressure

no changein humans1

1 study
  1. Diastolic blood pressure was not clearly linked with SCORE2 in humans (diastolic BP >=70 mmHg with systolic BP < 120 mmHg after adjustment for systolic BP).

    “Their slightly higher SCORE2 was attributable to higher systolic BP and age, and was no longer significant after adjustment for systolic BP.”

    Humansdiastolic BP >=70 mmHg with systolic BP < 120 mmHg after adjustment for systolic BPn = 1,394

    Impact of the new 2024 ESC blood pressure classification in a low-risk cohort: the 70 mmhg diastolic threshold may reduce risk discrimination in primary prevention

    Journal of hypertension

More on Diastolic blood pressure

Hyperuricemia

no changein humans1

1 study
  1. Hyperuricemia was not clearly linked with SCORE2 in humans (non-diabetic hypertensive patients).

    “There was no significant difference in the median SCORE2 in patients with or without hyperuricemia.”

    Humansnon-diabetic hypertensive patientsn = 588

    Hyperuricemia is not associated to cardiovascular risk assessed using SCORE2 in non-diabetic hypertensive patients aged 40 to 69 years in North Cameroon

    Annales de cardiologie et d'angeiologie

More on Hyperuricemia

ACP5

upin humans1

1 study
  1. ACP5 is linked with better SCORE2 in humans.

    “Addition of the 4 proteins to SCORE2 and SCORE2-Diabetes (for people without and with DM, respectively) improved the population-level discrimination, classification and calibration of these models.”

    Humans

    Analysis of the diabetic arterial transcriptome to define novel biomarkers of macrovascular disease

    medRxivPreprint

More on ACP5

TSM-associated metabolomic signature

upin humans1

1 study
  1. TSM-associated metabolomic signature is linked with better SCORE2 in humans (AUC 0.584 to 0.660).

    “Adding TSM or the metabolomic signature to SCORE2 improved 10‐year risk discrimination (area under the curve 0.584 to 0.657 and 0.660, respectively)”

    Humansfemalesn = 67,582

    Integrating menopause duration and plasma metabolomics enhances cardiovascular risk stratification in aging women

    npj aging

More on TSM-associated metabolomic signature

Neuropathic pain

no changein humans1

1 study
  1. Neuropathic pain was not clearly linked with SCORE2 in humans (hand osteoarthritis) (5.6 ± 3.7 versus 6.2 ± 3.3%; p = 0.38).

    “There was no difference in SCORE2 between hand osteoarthritis patients with (n = 60) and without (n = 50) neuropathic-like pain”

    Humanshand osteoarthritisn = 110

    Prevalence of comorbidities and cardiovascular risk factor management in hand osteoarthritis: a cross-sectional study

    Rheumatology international

More on Neuropathic pain

Associations

27

Cardiovascular disease

upin humans5

5 studies
  1. SCORE2 predicts cardiovascular disease in humans (without prior CVD) (C-index 0.75 (95%CI: 0.75-0.76)).

    “For SCORE2, SCORE2-Diabetes, and SCORE2-OP the C-index values were 0.75 (95%CI: 0.75-0.76), 0.71 (0.71-0.71) and 0.65 (0.65-0.65), respectively.”

    Humanswithout prior CVD

    Using population-wide electronic health records for timely contemporary assessment of cardiovascular disease risk prediction model performance: COVID-19 impact on the SCORE2 models

    European journal of preventive cardiology

  2. SCORE2 predicts cardiovascular disease in humans (general population cohort) (AROC 0.762).

    “The area under the receiver operating curve (AROC) was 0.762 in Mexico and 0.718 in Portugal.”

    Humansgeneral population cohortmean follow-up 9.7 yearsn = 95,660

    Validation of the European SCORE2 algorithm in one European and one Latin-American cohort studies with contrasting populations

    European heart journal. Quality of care & clinical outcomes

  3. SCORE2 predicts cardiovascular disease in humans (cancer) (C-statistic 0.693 [95% CI 0.643-0.743]).

    “C-statistics for SCORE2 was 0.693 [95% confidence interval (CI) 0.643-0.743]”

    Humanscancer8.8 yearsn = 1,622

    External validation of the systematic coronary risk evaluation 2 (SCORE2) and SCORE2-older persons in cancer patients

    European journal of preventive cardiology

  4. SCORE2 predicts cardiovascular disease in humans (without baseline CVD or diabetes) (AUC 0.75 (95% CI 0.74-0.77)).

    “The area under the curve (AUC) was 0.75 (95% CI 0.74-0.77), with underestimation of risk in men [O/E 1.4 (95% CI 1.3-1.6)] and overestimation in women”

    Humanswithout baseline CVD or diabetes10-yearn = 19,560

    Validation of Systematic Coronary Risk Evaluation 2 (SCORE2) and SCORE2-Older Persons in the EPIC-Norfolk prospective population cohort

    European journal of preventive cardiology

  5. SCORE2 predicts cardiovascular disease in humans (C-statistics ranging from 0.67 to 0.81).

    “These were extensively validated with excellent calibration and C-statistics ranging from 0.67 to 0.81.”

    Review

    New Way to "SCORE" Risk: Updates on the ESC Scoring System and Incorporation into ESC Cardiovascular Prevention Guidelines

    Current cardiology reports

More on Cardiovascular disease

Cognitive impairment

upin humans2OR 3.65

2 studies
  1. SCORE2 predicts cognitive impairment in humans (AUC 0.742 (0.62-0.85)).

    “SCORE2 alone discriminated CI with AUC 0.742 (0.62-0.85).”

    Humansfemalesn = 89

    SCORE2 cardiovascular risk score for cognitive impairment in women aged 40 years and above: a pragmatic triage signal in primary care - a single-center family medicine feasibility study with machine learning support

    Frontiers in medicine

  2. SCORE2 is associated with cognitive impairment in humans (per 5% absolute increase) (OR 3.65 (95% CI 1.67-7.98)).

    “Each 5% absolute SCORE2 increase conferred OR 3.65 (95% CI 1.67-7.98, p = 0.001); High vs. Low OR 6.21 (1.85-20.86, p = 0.003).”

    Humansper 5% absolute increasefemalesn = 89

    SCORE2 cardiovascular risk score for cognitive impairment in women aged 40 years and above: a pragmatic triage signal in primary care - a single-center family medicine feasibility study with machine learning support

    Frontiers in medicine

  3. SCORE2 is linked with a higher risk of cognitive impairment in patients with type 2 diabetes mellitus and/or atrial fibrillation (+2.40% per 1% increase in SCORE2).

    “In DM-2 and/or AF patients, an increase of 1% in SCORE2 was associated with an elevation of 2.40% in the odds of CD”

    Humansin patients with type 2 diabetes mellitus and/or atrial fibrillation

    Relationship Between Depression and Decreased Activity Level and Cognitive Impairment in Patients with Diabetes Mellitus Type 2 and/or Atrial Fibrillation

    Journal of clinical medicine

More on Cognitive impairment

Smoking

upin humans2

2 studies
  1. Smoking is associated with SCORE2 in humans (healthy workers undergoing occupational surveillance) (β = 1.40, 95% CI 1.07–1.74).

    “Higher SCORE2 was associated with smoking (β = 1.40, 95% CI 1.07–1.74)”

    Humanshealthy workers undergoing occupational surveillancen = 5,956

    Score 2 Cardiovascular Risk Assessment in Healthcare and Public Service Workers in Northeastern Italy

    Journal of occupational and environmental medicine

  2. Smoking is associated with SCORE2 in humans (evaluated by SCORE2/SCORE2-OP risk assessments).

    “Key risk factors included older age, smoking, high systolic blood pressure, and high non-HDL cholesterol.”

    Humansevaluated by SCORE2/SCORE2-OP risk assessmentsn = 24,434

    Cardiovascular risk profile with SCORE2 and SCORE2-OP: comparing Portugal, Spain, Italy, and France using the new European predictive models

    Frontiers in cardiovascular medicine

More on Smoking

Dementia

upin humans2

2 studies
  1. SCORE2 is linked with a higher risk of dementia in patients with type 2 diabetes mellitus and/or atrial fibrillation (+4.30% per 1% increase in SCORE2).

    “and of 4.30% of dementia.”

    Humansin patients with type 2 diabetes mellitus and/or atrial fibrillation

    Relationship Between Depression and Decreased Activity Level and Cognitive Impairment in Patients with Diabetes Mellitus Type 2 and/or Atrial Fibrillation

    Journal of clinical medicine

  2. SCORE2 is linked with a higher risk of dementia in humans (C-index 0.750 (95% CI: 0.745 to 0.755)).

    “higher SCORE2 risk was associated with higher risks of all-cause dementia, AD, VD, and all-cause mortality.”

    Humans12.8 yearsn = 429,033

    Prediction Abilities of SCORE2 Risk Algorithms for Incident Dementia and All-Cause Mortality: Results From the UK Biobank Cohort Study

    The journals of gerontology. Series A, Biological sciences and medical sciences

More on Dementia

Arterial occlusive events

upin humans1

1 study
  1. SCORE2 is associated with arterial occlusive events in humans (high to very high vs low-intermediate risk) (69.2% vs. 46.5%, p < 0.001).

    “Patients with a high to very high SCORE2/SCORE2-OP risk showed a significantly higher incidence rate of AOEs (69.2% vs. 46.5%, p < 0.001).”

    Humanshigh to very high vs low-intermediate risk

    The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib

    Annals of hematology

  2. SCORE2 predicts arterial occlusive events in humans (CML patients treated with nilotinib or ponatinib) (hazard ratio = 2.2; 95% confidence interval = 1.1-4.5).

    “Only the SCORE2/SCORE2-OP risk was confirmed as a significant predictive factor (p = 0.028; hazard ratio = 2.2; 95% confidence interval = 1.1-4.5).”

    HumansCML patients treated with nilotinib or ponatinib

    The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib

    Annals of hematology

More on Arterial occlusive events

Frailty

upin humans1RR 3.58

1 study
  1. SCORE2 predicts frailty in humans (AUC 0.759 in ELSA, 0.744 in HRS).

    “SCORE2 algorithm showed good accuracy for predicting accelerated frailty increase (area under the curve [AUC] in ELSA: 0.759; HRS: 0.744), with better performance than the SCORE”

    Humans

    Utility of SCORE2 risk algorithm for predicting life course accelerated frailty and physical function decline

    Journal of cachexia, sarcopenia and muscle

  2. SCORE2 is linked with a higher risk of frailty in humans (RR 3.58, 95% CI [3.22, 3.98]).

    “Each 10% increment in SCORE2 risk was associated with the higher risk of accelerated frailty increase (risk ratio [RR]: 3.58, 95% confidence interval [CI] [3.22, 3.98], P < 0.001 in ELSA”

    Humans

    Utility of SCORE2 risk algorithm for predicting life course accelerated frailty and physical function decline

    Journal of cachexia, sarcopenia and muscle

Occupational role

mixedin humans1

1 study
  1. Occupational role is associated with SCORE2 in humans.

    “Technical/logistics staff and municipal police officers had the highest estimates, whereas administrative and healthcare workers had lower scores.”

    Humanstechnical/logistics staff and municipal police officers compared with administrative and healthcare workersn = 5,956

    Score 2 Cardiovascular Risk Assessment in Healthcare and Public Service Workers in Northeastern Italy

    Journal of occupational and environmental medicine

More on Occupational role

Body mass index

upin humans1

1 study
  1. Body mass index is associated with SCORE2 in humans (healthy workers undergoing occupational surveillance) (β = 0.11 per kg/m2, p<0.001).

    “Higher SCORE2 was associated with smoking (β = 1.40, 95% CI 1.07–1.74), higher BMI (β = 0.11 per kg/m2, p<0.001), and occupational role.”

    Humanshealthy workers undergoing occupational surveillancen = 5,956

    Score 2 Cardiovascular Risk Assessment in Healthcare and Public Service Workers in Northeastern Italy

    Journal of occupational and environmental medicine

Absolute ASCVD risk

downin humans1

1 study
  1. SCORE2 predicts absolute ASCVD risk in humans (Voluntary screening cohort C2; published score) (Underprediction; observed-to-expected ratio 3.54).

    “In C2, all three underpredicted (3.43, 4.94 and 3.54).”

    HumansVoluntary screening cohort C2; published score6.75 yearsn = 2,554

    Recalibration of four cardiovascular risk prediction scores in two Abu Dhabi cohorts

    Research SquarePreprint

Major adverse cardiovascular events

upin humans1HR 1.82

1 study
  1. SCORE2 is associated with major adverse cardiovascular events in humans (Without established cardiovascular disease) (HR 1.82, 95% CI 1.57–2.10; score contrast not specified).

    “Both LE8 (total score, domains, and number of optimal components) and SCORE2 were significantly associated with MACE”

    HumansWithout established cardiovascular diseaseMedian follow-up of 8.3 years53% womensn = 2,938

    Life’s Essential 8 and SCORE2 for cardiovascular risk prediction in a middle-aged general population: the Akershus Cardiac Examination 1950 Study

    ESC Congress 2026 abstract

Contributing microRNA expression

downin humans1

1 study
  1. SCORE2 is associated with contributing microRNA expression in humans.

    “Most contributing microRNAs (miRs) exhibited reduced expression, consistent with de-repression of target genes regulating cell turnover, immunity and carbohydrate metabolism.”

    Human trialsubcutaneous adipose tissuen = 66

    Integrated adipose tissue transcriptomic and miRNA remodeling identifies molecular pathways associated with residual cardiovascular risk after weight loss

    Cardiovascular diabetology

More on Contributing microRNA expression

mTOR signaling

upin humans1

1 study
  1. SCORE2 is associated with mTOR signaling in humans.

    “Higher SCORE2 was associated with AT expression patterns involving immune responses, apoptosis, mTOR signaling, mitochondrial respiratory chain activity and glucose metabolism, including glycolysis, insulin signaling and pyruvate oxidation.”

    Human trialsubcutaneous adipose tissuen = 66

    Integrated adipose tissue transcriptomic and miRNA remodeling identifies molecular pathways associated with residual cardiovascular risk after weight loss

    Cardiovascular diabetology

More on mTOR signaling

All 27

How this record changed

  1. Summary rewritten as its findings changed.

    As it read before

    One human study links higher SCORE2 to cognitive impairment in women and reports predictive performance. A human trial reports improvement with caloric restriction in obesity, whereas another human study reports no effect of exercise in people younger than 70.

  2. Summary written from the findings.

Latest

Dec 2025: 6Jan 2026: 14Feb 2026: 17Mar 2026: 25Apr 2026: 7May 2026: 1Jun 2026: 8Jul 2026: 5Aug 2026: 18Sep 2026: 11Oct 2026: 49Nov 2026: 14175 papers in 12 months
Arquivos Brasileiros de Cardiologia

Models estimate cardiovascular risk in Latin America and the Caribbean

External validation in 132,512 people yielded an overall risk-ranking score of 0.740, ranging from 0.674 to 0.789 across cohorts.External validation in 132,512 people yielded an overall risk-ranking score of 0.740, ranging from 0.674 to 0.789 across cohorts.

Cohort · 132,512 peopleCardiovascular disease
AHA Scientific Sessions 2026 Abstract

Repeated heart recordings improved AI risk prediction in patients

Across three hospital cohorts, models using repeated heart recordings outperformed a single-recording model for 11 of 13 outcomes.Across three hospital cohorts, models using repeated heart recordings outperformed a single-recording model for 11 of 13 outcomes.

Cohort studyBiomarkers

See all 233 papers on SCORE2